- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02778581
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
Randomized, Double Blind, Placebo Controlled Prospective Study, to Evaluate the Effect of a Vegetal Oil in the Disease's Natural Evolution in Patients Diagnosed With Cognitive Impairment or Mild to Moderate Alzheimer Disease.
연구 개요
상태
상세 설명
The cognitive impairment syndrome is defined as a decrease of the intellectual performance with respect to a previous step in time. The Cognitive impairment has to be considered as a functional alteration with a continuous and physiological evolution in which happen a set of different circumstances:
- A increasing and normal reduction, that appears after the age of sixty, also known as Age-associated memory impairment (AAMI)
- A mild cognitive impairment (MCI), with a recent and mild loss of memory, but higher to that expected because of patient's age and educational level.
- A severe pathological decrease of the mental abilities, also known as, depending on its characteristics: Severe cognitive impairment (SCI), senile dementia and Alzheimer's disease (1).
In the next years it is expected that this disease will become one of the main health and aged-related problem in aged people.(2) Nowadays, there are 35,6 million people with any kind of dementia, and it is estimated that every year, 7,7 million of new patients are diagnosed. (3) The amount of people affected will probably duplicate every 20 years, if effective treatments to stop its evolution are not developed. The forecast estimate up to 81,1 million of patients in 2040, which make this disease in a XXI century real epidemic.(4)
Before reaching the level of dementia, SCI or Alzheimer's disease, the patient will suffer a progressive mild cognitive impairment. In this level, the disease can be early diagnosed and it would be worth to act on it.
Evidences of the Polyunsaturated oils use on the prevention and/or treatment of cognitive impairment.
Polyunsaturated fatty acids (PUFA) can help to improve the cognitive functions. Neuronal tissues, as the brain, retina and the neurone-covering membranes (myelin) include high levels of PUFA. (5) PUFA's act on the order transmission in the Nervous System. Population studies reported the beneficial effect of fish oil, with a high PUFA concentration, on the memory of patients suffering a mild cognitive impairment. (6) It can be also beneficial for Alzheimer's patients, as they are deficient in PUFA's. A diet rich in PUFA'S can improve the cognitive function on patients con cognitive impairment and Alzheimer's disease. (6-8) Epidemiological studies suggest that oils rich in short chain PUFA, should play a beneficial role stopping the initial progression of Alzheimer's disease.
The previous data confirm the possibility of a beneficial effect of the product to study (a mixture of vegetable oils, rich in triglyceride and lecithins) due to the common characteristic of the product with those PUFA's already marketed.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Vicente Navarro-López, MD
- 이메일: vnavarro@ucam.edu
연구 연락처 백업
- 이름: Miguel A Carrión-Gutiérrez, PhD
- 이메일: miguelcarrion65@gmail.com
연구 장소
-
-
Alicante
-
Elche, Alicante, 스페인, 03293
- 모병
- Hospital Universitario Vinalopó
-
연락하다:
- Ana Fríes-Ramos, MD
- 이메일: afries@vinaloposalud.com
-
Torrevieja,, Alicante, 스페인, 03186
- 모병
- Hospital Universitario de Torrevieja
-
연락하다:
- Rosa Vela-Yebra, MD
- 이메일: rvela@torrevieja-salud.com
-
연락하다:
- María A Méndez-Miralles, MD
- 이메일: mamendez@torrevieja-salud.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- informed consents signed by patients and/or caretaker
- The patient has to fulfil dementia clinical criteria.
- Age between 55 and 85 years old.
- MMSE score between 18 and 26.
- The patient can fulfil all neuropsychologic test, according to investigator.
- The patient has to be always with his/her caretaker during monitorization visits
- The caretaker has to be in regular contact with the patient, knowing his/her situation and participation in the study.
- The caretaker has to check four times per week, at least, the product intake, as well as the routine medication and his/her dietetic habits.
- Both caretaker and patient have to be able to complete the product intake during all the length of the study, according to the main investigator.
Exclusion Criteria:
- Patient and/or caretaker not being able to understand and agree in writing their participation in the study.
- Patient disability to oral intake of products.
- Known allergy to any of the product components (active and placebo)
- Evidence of suffering other neuropsychiatric disturbances apart of dementia as: Parkinson disease, psychotic disturbance, bipolar depression.
- regular intake of alcohol higher than 45 g ethanol/day, during the year before study inclusion.
- Any known concurrent malignant pathology in the moment of study inclusion, or severe metabolic, cardiovascular, renal, hepatic, or gastrointestinal disease that cannot allow the ending of the study according the investigator.
- Any analytical abnormality during the screening, apart from: Creatinine no less than 1.7 mg/dL; low levels of Vitamin B12, and TSH abnormal values.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Lipidic Blend 1
Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
|
daily intake of the content of one 45 mL bottle containing the product
|
활성 비교기: Lipidic Blend 2
Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
|
daily intake of the content of one 45 mL bottle containing the product
|
위약 비교기: Placebo
Glass bottle with 45 ml of Olive oil. 1 bottle per day
|
daily intake of the content of one 45 mL bottle containing olive oil
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Changes in Mini-Mental State Examination (MMSE) score
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
Changes in Global Clinical Dementia Rating (CDR) score
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Changes in systemic oxidative parameters in periferic blood samples (Nitric Oxyde)
기간: baseline, 12 month
|
baseline, 12 month
|
|
Changes in systemic oxidative parameters in periferic blood samples (Malondialdehyde (MDA))
기간: baseline, 12 month
|
baseline, 12 month
|
|
Changes in beta-amyloid protein concentration
기간: baseline, 12 month
|
Changes in mean values on high sensitivity beta-amyloid 1-40 and 1-42 protein and TAU-protein in cerebrospinal fluid on those patients with a new diagnose of mild to moderate cognitive impairment, that require an initial lumbar puncture and a new lumbar puncture to control evolution at the end of teh study.
|
baseline, 12 month
|
Changes in TAU-Protein concentration
기간: baseline, 12 month
|
Changes in mean values on high sensitivity beta-amyloid 1-40 and 1-42 protein and TAU-protein in cerebrospinal fluid on those patients with a new diagnose of mild to moderate cognitive impairment, that require an initial lumbar puncture and a new lumbar puncture to control evolution at the end of teh study.
|
baseline, 12 month
|
Changes in regular treatment for the cognitive impairment
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
|
Changes in dietetic habits
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
|
Changes in Barthel score
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
|
Changes in Morisky-Green score
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
|
changes in weight
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
baseline, 3 month, 6 month, 9 month, 12 month
|
|
Number of adverse events
기간: baseline, 3 month, 6 month, 9 month, 12 month
|
Number of adverse events related or nonrelated to the study or placebo products.
|
baseline, 3 month, 6 month, 9 month, 12 month
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Vicente Navarro-López, MD, Universidad Católica San Antonio de Murcia
간행물 및 유용한 링크
일반 간행물
- Kueider AM, Parisi JM, Gross AL, Rebok GW. Computerized cognitive training with older adults: a systematic review. PLoS One. 2012;7(7):e40588. doi: 10.1371/journal.pone.0040588. Epub 2012 Jul 11.
- Luck T, Luppa M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord. 2010;29(2):164-75. doi: 10.1159/000272424. Epub 2010 Feb 11.
- Coronado M, et al. Los ácidos grasos omega-3 y omega-6: Nutrición, bioquímica y salud. REB 25(3) 2006: 72-79
- Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr. 2012 Jan;3(1):1-7. doi: 10.3945/an.111.000893. Epub 2012 Jan 5.
- Lee LK, Shahar S, Chin AV, Yusoff NA. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013 Feb;225(3):605-12. doi: 10.1007/s00213-012-2848-0. Epub 2012 Aug 30.
- Larrieu S, Letenneur L, Berr C, Dartigues JF, Ritchie K, Alperovitch A, Tavernier B, Barberger-Gateau P. Sociodemographic differences in dietary habits in a population-based sample of elderly subjects: the 3C study. J Nutr Health Aging. 2004;8(6):497-502.
- Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, Barberger Gateau P, Berr C, Bonnefoy M, Dartigues JF, de Groot L, Ferry M, Galan P, Hercberg S, Jeandel C, Morris MC, Nourhashemi F, Payette H, Poulain JP, Portet F, Roussel AM, Ritz P, Rolland Y, Vellas B. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging. 2007 Mar-Apr;11(2):132-52.
- Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev. 2003 Nov;8(4):410-25.
- Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging. 2004;8(3):163-74.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Lipidic Blend 1에 대한 임상 시험
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth... 그리고 다른 협력자들완전한
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department of Defense; Defence... 그리고 다른 협력자들완전한